STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
Shunsuke Kimura,Petri Polonen,Lindsey Montefiori,Kenneth Caldwell,Ilaria Iacobucci,Chelsey Chen,Anthony Brown,Katie Han,Yen-Chun Liu,Yunchao Chang,Zhongshan Cheng,Zhou Yinmei,Chun Shik Park,Sharnise Mitchell,Noemi Reyes,Allen Yeoh,Andishe Attarbaschi,Andrew Moore,Atsushi Manabe,Barbara Buldini,Kean Hui Chiew,Chi Kong Li,Ching-Hon Pui,Chunxu Qu,Daisuke Tomizawa,Elisabeth Paietta,Franco Locatelli,Gabriele Escherich,Gao Qingsong,Hannah Elisa Muhle,Hanne Vibeke Marquart,Hester A. De Groot-Kruseman,Jacob M. Rowe,Jan Stary,Jan Trka,John Kim Choi,Jules P. P. Meijerink,Junko Takita,Katarzyna Pawinska-Wasikowska,Kjeld Schmiegelow,Mariko Eguchi,Martin Schrappe,Martin Zimmermann,Masatoshi Takagi,Melissa Maybury,Michael Svaton,Michaela Reiterova,Michal Kicinski,Motohiro Kato,Orietta Spinelli,Pauline Mazilier,Paul G. Thomas,Riccardo Masetti,Rishi Sury Kotecha,Rob Pieters,Sarah Elitzur,Selina M. Luger,Shuhong Shen,Sima Jeha,Steven M. Kornblau,Szymon Skoczen,Takako Miyamura,Tiffaney Vincent,Toshihiko Imamura,Valentino Conter,Yanjing Tang,Zhaohui Gu,Kathryn G. Roberts,David T. Teachey,Kristine R. Crews,Cheng,Jun J. Yang,Hiroto Inaba,Charles G. Mullighan
DOI: https://doi.org/10.1182/blood-2023-178688
IF: 20.3
2023-01-01
Blood
Abstract:Background The prognosis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has improved with minimal residual disease (MRD)-stratified therapy, however, gamma delta T cell receptor positive (γδ) T-ALL remains a high-risk (HR) group. Limited studies have explored the clinical and genomic characteristics of γδ T-ALL, prompting us to conduct a comprehensive analysis of this entity and to identify determinants of outcome. Methods Through a consortium of 13 groups, we assembled a cohort of 200 patients up to 25 years of age with γδ T-ALL enrolled in clinical trials between 2000 and 2018. Clinical data of patients with non-γδ T-ALL enrolled on the same clinical trials were collected (n = 1,067). Complete remission (CR) was defined when bone marrow (BM) showed M1 cytomorphology and/or MRD <1% without evidence of extramedullary disease at end of induction/consolidation (EOI/EOC) and failure to achieve CR was considered treatment failure. A total of 76 γδ T-ALL samples were analyzed by whole genome (WGS) and/or transcriptome (RNAseq) sequencing. Results The frequency of γδ T-ALL was 8.0% of T-ALL cases. Patients with γδ T-ALL exhibited a higher rate of poor prednisone response ( P<0.01), MRD >1% at day 15 ( P<0.01), at EOI ( P<0.01) and EOC ( P<0.01), compared to non-γδ T-ALL cases. Furthermore, patients with γδ T-ALL showed significantly worse 5-year event free survival (EFS, 65% v. 78%, P<0.01) and overall survival (OS, 77% vs 83%, P=0.048). Almost all relapses of γδ T-ALL were isolated BM, while the central nervous system was the main site of relapse in non-γδ T-ALL, suggesting slow treatment response and chemo-resistance to the current treatment in γδ T-ALL. However, γδ T-ALL showed a higher rate of toxic death during treatment (7.6% vs 4.0%, P<0.01), suggesting the need for different therapeutic strategies and risk-classification, rather than treatment intensification. Strikingly, patients less than 3 years of age with γδ T-ALL exhibited significantly poor EFS (33% v. 70% [3-10 years] and 73% [>10], P<0.01) and OS (49% v. 78% [3-10] and 82% [>10], P< 0.01) ( Fig. A), a difference not observed in non-γδ T-ALL. MRD >1% at EOI showed poor EFS (51% v. 96% [MRD<0.01%] and 91% [1%>MRD>0.01%], P<0.01) and OS (66%). Integrated analysis of WGS and RNAseq identified enrichment of several genomic subtypes in γδ T-ALL, including STAG2/LMO2, hyperdiploidy with recurrent gains of chromosomes 8, 10, 11, 13q and 19, a recently identified “LMO2 γδ-like” subtype with distinct gene expression and LMO2/MYC/MYCN alterations, TLX3-rearranged (-R), and PICALM::MLLT10. No TAL1 nor TLX1-R were detected. STAG2/LMO2 was associated with age at diagnosis before 3 years, and extremely poor outcome, with 4 out of 5 cases dying within three years of diagnosis ( Fig. B). Of 24 STAG2/LMO2 T-ALL (additional 5 non-γδ, 13 TCR unknown cases), 22 of which were diagnosed by age three. All STAG2/LMO2 cases had alterations resulting in LMO2 activation and STAG2 inactivation, most commonly a single rearrangement between these two genes, and upregulation of HBE1, the LIN28-let7 pathway and stem cell proliferation pathways, suggesting a fetal hematopoietic origin. STAG2 has a critical role in the maintenance of enhancer-promoter looping mediated by the cohesin complex. To examine the consequences of STAG2 alterations, we performed integrated genomic/epigenomic analysis of the STAG2/LMO2 (MOLT-14 and PER-117) and STAG2 knockout (KO)/addback T-ALL lines. Chromatin loop sizes defined by H3K27ac HiChIP was highest in STAG2/LMO2 lines compared to other T-ALL. Following restoration of STAG2 expression in MOLT-14, CD34 and ID1/2 were down-regulated and H3K27ac was enriched in pathways related to T-cell differentiation. STAG2 KO in the non- STAG2/LMO2, LMO2-activated line PF382 identified genes also upregulated in STAG2/LMO2 primary samples, including CDK4 and STAG1. STAG2 KO lines exhibited partial compensation of STAG2 binding sites by STAG1 and upregulation of γδ-related genes, RORC and ID1/3. High throughput screening of 2,050 small molecules identified efficacy of HDAC, CDK and PARP inhibitors in STAG2/LMO2 lines. Conclusion Very young onset γδ T-ALL, but not non-γδ T-ALL, is enriched for the STAG2/LMO2 subtype and is a very high risk form of T-ALL. STAG2 loss perturbs chromatin organization and hematopoietic differentiation. Moreover, we demonstrate efficacy of novel therapeutic approaches that are needed to cure this form of leukemia.